GuidelineJournal of the American Academy of Dermatology2020
National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1.
Guideline in Journal of the American Academy of Dermatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 2 syntheses or guidelines pooled it, 49 citations in OpenAlex.
- Systemic glucocorticoid use and the occurrence of flares in psoriatic arthritis and psoriasis: a systematic review.Rheumatology (Oxford, England) · 2022Pooled it
- National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2-Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments.Journal of the American Academy of Dermatology · 2021Guideline
- The Global Burden and Temporal Trends of Psoriasis, 1990-2021: Implications From the COVID-19 Pandemic.Health science reports · 2026Article
- Impact of Treatment Interruption on the Effectiveness of Interleukin (IL)-17A Inhibitors in Plaque Psoriasis: A Retrospective Analysis.International journal of general medicine · 2025Article
- Vaccination Rates in Patients with Chronic Inflammatory Skin Diseases and Immunomodulatory Systemic Therapies-Vaccinations against SARS-CoV-2, Influenza Virus or Varicella Zoster Virus.Life (Basel, Switzerland) · 2024Article
- Basic Susceptibility of Patients with Psoriasis under Systemic Therapy for Respiratory Infections: Data from the German Psoriasis Registry PsoBest.Journal of clinical medicine · 2024Article
- The patient perspective on vaccine uptake in adults with psoriasis and eczema.Archives of dermatological research · 2023Article
- A case of psoriatic spondyloarthritis exacerbation triggered by COVID-19 messenger RNA vaccine.Journal of the European Academy of Dermatology and Venereology : JEADV · 2022Article
- Acute exacerbation of psoriasis after COVID-19 Pfizer vaccination.Proceedings (Baylor University. Medical Center) · 2022Article
- Likelihood of COVID-19 Vaccination Among Individuals Living With Psoriatic Disease: Results From a Large Real-World Survey.Journal of psoriasis and psoriatic arthritis · 2022Article
- The Use of Biologics During the COVID-19 Pandemic.Dermatologic clinics · 2021Review
- New Frontiers in Psoriatic Disease Research, Part II: Comorbidities and Targeted Therapies.The Journal of investigative dermatology · 2021Review
- Describing the burden of the COVID-19 pandemic in people with psoriasis: findings from a global cross-sectional study.Journal of the European Academy of Dermatology and Venereology : JEADV · 2021Article
- Immediate effect of the COVID-19 pandemic on patient health, health-care use, and behaviours: results from an international survey of people with rheumatic diseases.The Lancet. Rheumatology · 2021Article
- Healthcare Resource Use in Patients with Immune-Mediated Conditions Treated with Targeted Immunomodulators During COVID-19 Pandemic: A Retrospective Claims Analysis.Advances in therapy · 2021Article
- Dermatology COVID-19 Registries: Updates and Future Directions.Dermatologic clinics · 2021Review
- How Coronavirus Disease 2019 Changed Dermatology Practice in 1 Year Around the World: Perspectives from 11 Countries.Dermatologic clinics · 2021Review
- Management of Psoriasis During the Coronavirus Disease 2019 Pandemic.The Journal of clinical and aesthetic dermatology · 2021Review
- Switching infliximab in psoriatic patients during COVID-19 pandemics: A real-life retrospective study comparing intra-versus interclass switching strategies.Dermatologic therapy · 2021Observational
- Influence of SARS-CoV-2 Virus Infection on the Course of Psoriasis during Treatment with Biological Drugs.Medicina (Kaunas, Lithuania) · 2021Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors at 16 institutions in 2 countries.
Funding
Abstract
objectiveTo provide guidance about management of psoriatic disease during the coronavirus disease 2019 (COVID-19) pandemic. STUDY
designA task force (TF) of 18 physician voting members with expertise in dermatology, rheumatology, epidemiology, infectious diseases, and critical care was convened. The TF was supplemented by nonvoting members, which included fellows and National Psoriasis Foundation (NPF) staff. Clinical questions relevant to the psoriatic disease community were informed by questions received by the NPF. A Delphi process was conducted.
resultsThe TF approved 22 guidance statements. The average of the votes was within the category of agreement for all statements. All guidance statements proposed were recommended, 9 with high consensus and 13 with moderate consensus. LIMITATIONS: The evidence behind many guidance statements is limited in quality.
conclusionThese statements provide guidance for the management of patients with psoriatic disease on topics ranging from how the disease and its treatments impact COVID-19 risk and outcome, how medical care can be optimized during the pandemic, what patients should do to lower their risk of getting infected with severe acute respiratory syndrome coronavirus 2 and what they should do if they develop COVID-19. The guidance is intended to be a living document that will be updated by the TF as data emerge.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.